We are live on ! Find out more
KPRX icon

Kiora Pharmaceuticals
KPRX

19 hedge funds and large institutions have $1.34M invested in Kiora Pharmaceuticals in 2021 Q3 according to their latest regulatory filings, with 8 funds opening new positions, 3 increasing their positions, 0 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

33% more first-time investments, than exits

New positions opened: 8 | Existing positions closed: 6

12% more funds holding

Funds holding: 17 → 19 (+2)

0.13% less ownership

Funds ownership: 0.15% → 0.01% (-0.13%)

90% less capital invested

Capital invested by funds: $13.7M → $1.34M (-$12.4M)

Holders
19
Holders Change
+2
Holders Change %
+11.76%
% of All Funds
0.33%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
8
Increased
3
Reduced
–
Closed
6
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Geode Capital Management
Geode Capital Management
Massachusetts
+$526K
2
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
+$122K
3
Jane Street
Jane Street
New York
+$82.4K
4
SCA
Sassicaia Capital Advisers
New York
+$58.6K
5
Vanguard Group
Vanguard Group
Pennsylvania
+$56.1K

Top Sellers

Rank Fund Capital Flow
1
AC
Armistice Capital
New York
-$12.2M
2
Renaissance Technologies
Renaissance Technologies
New York
-$328K
3
PHP
Parkman Healthcare Partners
Connecticut
-$275K
4
Two Sigma Advisers
Two Sigma Advisers
New York
-$139K
5
Two Sigma Investments
Two Sigma Investments
New York
-$99K
Name Holding Trade Value Shares
Change 		Change in
Stake
Geode Capital Management
1
Geode Capital Management
Massachusetts
$534K +$526K +619 +1,510%
Vanguard Group
2
Vanguard Group
Pennsylvania
$341K +$56.1K +66 +19%
T. Rowe Price Associates
3
T. Rowe Price Associates
Maryland
$115K +$122K +143 New
Jane Street
4
Jane Street
New York
$78K +$82.4K +97 New
SCA
5
Sassicaia Capital Advisers
New York
$56K +$58.6K +69 New
BlackRock
6
BlackRock
New York
$47K – – –
TCM
7
Tuttle Capital Management
Connecticut
$41K +$42.5K +50 New
TRCT
8
Tower Research Capital (TRC)
New York
$31K +$32.3K +38 New
XT
9
XTX Topco
Cayman Islands
$31K +$33.1K +39 New
CS
10
Credit Suisse
Switzerland
$23K +$23.8K +28 New
HF
11
HRT Financial
New York
$22K +$23.8K +28 New
US Bancorp
12
US Bancorp
Minnesota
$6K – – –
Royal Bank of Canada
13
Royal Bank of Canada
Ontario, Canada
$4K – – –
SFP
14
Sterling Financial Planning
New Jersey
$3K – – –
Osaic Holdings
15
Osaic Holdings
Arizona
$3K +$2.55K +3 +300%
NFSG
16
Newbridge Financial Services Group
Florida
$2K – – –
AFG
17
Albion Financial Group
Utah
$1K – – –
Morgan Stanley
18
Morgan Stanley
New York
$1K – – –
UBS Group
19
UBS Group
Switzerland
$1K – – –
AC
20
Armistice Capital
New York
– -$12.2M -9,296 Closed
Renaissance Technologies
21
Renaissance Technologies
New York
– -$328K -251 Closed
PHP
22
Parkman Healthcare Partners
Connecticut
– -$275K -210 Closed
Two Sigma Advisers
23
Two Sigma Advisers
New York
– -$139K -106 Closed
Two Sigma Investments
24
Two Sigma Investments
New York
– -$99K -75 Closed
Citadel Advisors
25
Citadel Advisors
Florida
– -$77K -59 Closed

KPRX Hedge Fund Activity: Q3 2021 in Review

19 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in Kiora Pharmaceuticals (KPRX) for Q3 2021, worth a combined $1.34M — down 90% from $13.7M a quarter earlier.

Buyers outnumbered sellers: 8 funds opened new KPRX positions and 6 closed out — a net gain of 2 holders — while 3 added to existing stakes and 0 trimmed.

The largest buyer was Geode Capital Management, adding an estimated $526K. The largest seller was Armistice Capital, exiting entirely with an estimated $12.2M sold.

  • 19 institutional investors held Kiora Pharmaceuticals (KPRX) as of Q3 2021, up from 17 in Q2 2021.
  • Funds reported $1.34M of Kiora Pharmaceuticals stock for Q3 2021, down 90% quarter-over-quarter.
  • 8 funds opened new Kiora Pharmaceuticals positions in Q3 2021 and 6 closed out, a net change of +2 holders.
  • The largest Kiora Pharmaceuticals buyer in Q3 2021 was Geode Capital Management, an estimated $526K added.
  • The largest Kiora Pharmaceuticals seller in Q3 2021 was Armistice Capital, an estimated $12.2M sold.

Based on aggregated 13F filings for Q3 2021.